Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 4, 2024JDDG Journal der Deutschen Dermatologischen GesellschaftOpen Access

SARS‐CoV‐2 reactive infectious mucocutaneous eruptions in adults treated with cyclosporine as first line treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAndrew McDermidUniversity of British ColumbiaKLKaitlyn LamUniversity of British ColumbiaYKYen Chen Kevin KoBC Cancer Agency

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

McDermid et al. (2024) studied this question.

synapsesocial.com/papers/6a5e2bbddec751667c70b2b8https://doi.org/10.1111/ddg.15417
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reactive infectious mucocutaneous eruption secondary to SARS-CoV-22021 · 35 citations
  2. 2Cyclosporin A inhibits the replication of diverse coronaviruses2011 · 249 citations
  3. 3Reactive infectious mucocutaneous eruption due to <scp>COVID</scp>‐19 with erythema‐multiforme‐like lesions and myeloid cells2022 · 10 citations
  4. 4Treatment of <i>Mycoplasma pneumoniae</i> -Induced Rash and Mucositis With Cyclosporine2019 · 41 citations